Feature
Conceiving, building, maintaining and refi ning a universal health system is an inordinately complex undertaking. Its effective implementation requires everything from political will consistently and strategically applied, to accurate epidemiological data and analysis, plus quality medical education and active citizen participation. It also takes resources-fi nancial, technological, pharmaceutical and professional-a perennial challenge for a small, economically-constrained island nation like Cuba. Indeed, even some highly developed nations like the United States have yet to achieve universal health coverage.
In Cuba's case, resource scarcity itself, coupled with the need to develop a sustainable health care model suffi ciently independent of global geopolitical and economic turbulence, has, paradoxically, led to the establishment of a key health system component: a robust domestic biopharmaceutical industry.
[1] A Global South leader in biotech R&D, Cuba produces innovative vaccines and therapies-many unique in the world-such as Heberprot-P, Nimotuzumab, VA-MENGOC-BC, and a synthetic antigen vaccine against Haemophilus infl uenzae b (Hib).
[2] While these products are the headline-makers, diagnostic systems and equipment designed, built and distributed by Havana's Immunoassay Center (CIE, the Spanish acronym) have quietly but consistently contributed to improving Cuban and global health for over two decades.
Background
Cuba's aggressive push to develop a domestic biotech sector dates to the early 1980s when a cluster of scientifi c research and manufacturing institutions were established to produce interferon, recombinant proteins and other biotech products. These institutions became the building blocks of Cuba's Scientifi c Pole, a scientifi c campus located in western Havana, which today comprises 24 research institutions and 58 manufacturing facilities, employs more than 7000 scientists and engineers [3] and collectively accounted for US$711 million in export earnings in 2011; this makes it the country's largest revenue-earning manufacturing industry after nickel. [4] Founded in 1987, CIE was one of the Scientifi c Pole's seminal institutions. CIE researchers challenged themselves to "look for technologies of the future, to see what we could do that could be applied throughout a national public health system," Director José Luis Fernández Yero told MEDICC Review. [5] By design, these technologies would need to be accessible to and appropriate for resource-scarce contexts; effective and effi cient; with coverage of as many people as possible. The goal was to apply these technologies in active screening programs for early diagnosis of infectious and chronic non-communicable diseases, as well as to congenital conditions that have a high medical and social impact or are major causes of morbidity or mortality in Cuba and thus targets for early intervention at the primary care level. [6] These include breast, colon and prostate cancers; Hepatitis B and C; HIV; dengue and diabetes.
Developing medical technologies for population health is only one piece of the puzzle, however. To be effective, such technologies must be applied rationally and through a coordinated strategy that includes laboratory networks to process diagnostic tests, trained professionals to interpret results, and maintenance programs to keep equipment functioning. By working closely with Cuba's Ministry of Public Health (MINSAP, the Spanish acronym) and the national programs applying the technologies, CIE products provide nationwide coverage for detection, surveillance and monitoring of the chief causes of death and years of productive life lost in Cuba.
Applying Technology to Improve Population Health
Several CIE technologies pre-date its founding. In 1981, Cuba began a pilot program using an ultramicroanalytic system (SUMA) to detect congenital malformations and in 1986 began providing screening for congenital hyperthyroidism in newborns-the second country in the hemisphere to do so, after Canada. [5] Today, CIE has a robust portfolio of 33 diagnostic tests used in the national health system for the detection, monitoring and evaluation of 19 diseases; they are regarded as the fi rst link in a chain of complementary and confi rmatory diagnostics.
These tests are used in active screening programs to identify risk factors in the population and permit early diagnosis in people who have, or are at greater risk for, a particular disease, even before the onset of symptoms. This increases therapeutic options, decreases complications and mortality, and improves quality of life. Early detection also lowers overall costs to the health system, since fewer patients will progress towards advanced stages of disease.
CIE also designs, develops and manufactures equipment and instruments used in diagnostic testing and the software need- This national network of laboratories and support centers signifi cantly impact quality of patient care. Previously, diagnostic testing was limited to the provincial capitals, meaning patients in outlying and remote municipalities had to wait for results to return to their primary care facility. Locating testing at municipality-based CEPAIs results in a more effi cient process, improved diagnostic quality and less stress for patients who get their test results more quickly. A procedural change is also improving care: whereas before patients were only notifi ed if they tested positive for a disease or condition, now they receive notifi cation regardless of the result. Decentralization of equipment maintenance is likewise impacting care, since it means faster service for broken equipment.
Immunodiagnostics: The Convergence of Biotech and Public Health
In Cuba, chronic non-communicable diseases account for some 60% of deaths a year, providing impetus to develop strategies and technologies for their diagnosis and monitoring. With this in mind, CIE introduced the SUMAsensor in 2008, a glucometer designed specifi cally for tropical climates (dipsticks individually packaged in aluminum blisters). Results appear in 25 seconds and the unit stores up to 220 results, displaying the date and time they were registered. Thus far, over 130,000 SUMAsensors and 26 million dipsticks have been distributed, 85% of them to insulin-dependent diabetics and the rest to health facilities. About 80% of insulin-dependent diabetics have received the glucometer, but the goal is to step up distribution to provide total coverage. In 2013, distribution to pregnant women with diabetes and people with type 2 diabetes will commence. Carmen Ramírez, an 84-year old diabetic from Regla, Havana, uses the SUMAsensor daily to measure her blood sugar levels. "It's so simple to use and I like being able to monitor my blood sugar from home. When there are fl uctuations, I go to my doctor and she knows exactly what my levels have been by looking at my glucometer," she told MEDICC Review. [7] In Search of Sustainability
Technological and diagnostic applications are particularly costly and often put health systems at the mercy of companies driven mainly by commercial considerations. Cuba's universal health system has adopted a social justice approach committed to care for all, addressing neglected diseases, and prioritizing vulnerable populations (which have little infl uence in an industry focused on the bottom line). Maintaining a universal health system and improving population health in a resource-scarce setting such as Cuba-where additional restrictions are imposed by the US embargo [8] -is a constant struggle.
Thus, CIE was founded, a domestic R&D center designed to ensure stable, sustainable product availability and relative independence from global volatility. The Center substitutes imports, and also exports its technology to fi nance research, development, manufacturing and distribution. Import substitution is fundamental to the formula's success, not only for the savings it provides the health system, but for the independence it represents for the sector. While all raw materials for CIE products must be purchased on the international market, 100% of the Center's technologies and instruments are manufactured domestically, representing an important degree of 'technology sovereignty' and sustainability. For example, import substitution of reagents used in CIE's diagnostic kits has saved the public health system US$300 million to date.
CIE sales abroad support this quest for sustainability: currently there are 469 laboratories using CIE products in # Feature some half a dozen countries, including Brazil, Argentina, China and Mexico. [9] The Cuban approach-locating laboratories near patients, CIE certifi cation courses for technicians, strategicallyplaced servicing and maintenance branches-is adapted to each site. The most popular products internationally are the SUMAsensor, reagents and an innovative cytology kit-one of CIE's newest products-developed jointly with the National Cancer Control Unit and the Cervical Cancer Early Diagnosis Program. International demand for CIE technologies and instruments (all of which undergo external evaluations and adhere to international quality control and certifi cation standards) is growing-so much so that CIE is currently working at double capacity and is expanding its physical plant to keep pace.
Sales of CIE products have rendered the institution fi nancially independent of all public funding, which the Center has not received since the 1990s, according to Director Fernández Yero. [5] Such solvency translates into savings for the national public health system as well, since it allows CIE to keep production costs and prices low. The SUMASCOPE is one example: this digital video colposcope costs US$10,000 on the international market, but CIE sells it to the Cuban public health system for US$300. It should be mentioned that low salaries for scientists, researchers and other professionals-an issue government has consistently promised to address as Cuba continues its program of economic reforms initiated in 2011-is another factor reducing production costs.
Conclusion
The Cuban biopharmaceutical industry is a patient-fi rst model characterized by prioritizing vulnerable populations; providing quality products at accessible prices and locations; and tailoring research and development to the health picture of the country. CIE and other institutions in the Scientifi c Pole pursue this strategy consistently and comprehensively in coordination with MINSAP and its national programs. While patient-based, the sector is increasingly looking for ways to become more effi cient to increase savings, and to more actively increase export revenuesboth critically important in today's uncertain global economy.
Knowing which technologies are needed to address pressing health needs-such as the burden of chronic non-communicable diseases facing the country-requires cooperation and input from primary care providers, specialists and epidemiologists. Having a unifi ed, universal system facilitates this cooperation.
